<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055133</url>
  </required_header>
  <id_info>
    <org_study_id>008-MPRA02</org_study_id>
    <nct_id>NCT00055133</nct_id>
  </id_info>
  <brief_title>A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiotech Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Paxceed™ is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of&#xD;
      Rheumatoid Arthritis (RA). The main objective of this study is to determine the effectiveness&#xD;
      of treatment with Paxceed™ in patients with RA. In RA, there is an increase in cell growth&#xD;
      and changes in cell function. The active substance in Paxceed™, paclitaxel, has undergone&#xD;
      clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an&#xD;
      agent that stops growth of cells and blocks certain types of cell function associated with&#xD;
      RA. Because of these effects, it is thought that Paxceed™ might alter the destructive course&#xD;
      of RA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micellar Paclitaxel for Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (i) Signed informed consent in accordance with applicable regulations&#xD;
&#xD;
        (ii) Males and females aged 21 to 70 years inclusive&#xD;
&#xD;
        (iii) Must have failed at least one DMARD&#xD;
&#xD;
        (iv) Rheumatoid Arthritis fulfilling 1987 ACR revised criteria&#xD;
&#xD;
        (v) Active RA as defined by:&#xD;
&#xD;
          -  ≥6 swollen and ≥9 tender joints&#xD;
&#xD;
          -  CRP ≥0.8 mg/dL or morning stiffness ≥45 minutes&#xD;
&#xD;
        (vi) If female and of child bearing potential, she must:&#xD;
&#xD;
          -  have a negative serum pregnancy test, and&#xD;
&#xD;
          -  be using two forms of an effective method of contraception (one form being a barrier&#xD;
             method) or be surgically incapable of bearing children or abstinent.&#xD;
&#xD;
        If male and heterosexual, he must:&#xD;
&#xD;
          -  agree to use condoms with spermicide throughout the study and for at least 12 weeks&#xD;
             following the last infusion.&#xD;
&#xD;
          -  vasectomy is an acceptable form of contraception for males and partners of females&#xD;
&#xD;
        (vii) Adequate venous access as defined by the Principal Investigator&#xD;
&#xD;
        (viii) If taking non-steroidal anti-inflammatory medications, must be on stable regimen for&#xD;
        four weeks prior to the Screening visit&#xD;
&#xD;
        (ix) If taking prednisone (≤ 10 mg) or equivalent, must be on stable regimen for four weeks&#xD;
        prior to Screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (i) Prior or current treatment with alkylating agents, or radiation&#xD;
&#xD;
        (ii) Treatment with colchicine within six months prior to Screening&#xD;
&#xD;
        (iii) Experimental anti-rheumatic drugs within 90 days (or five half-lives, whichever is&#xD;
        longer) prior to screening&#xD;
&#xD;
        (iv) DMARD therapy four weeks prior to Baseline visit&#xD;
&#xD;
        (v) Intra-articular corticosteroids four weeks prior to the Screening visit&#xD;
&#xD;
        (vi) Bedridden or wheelchair bound patients&#xD;
&#xD;
        (vii) Pregnant or lactating females&#xD;
&#xD;
        (viii) Interstitial lung disease&#xD;
&#xD;
        (ix) Clinically significant cardiac risk factors, including a history of congestive heart&#xD;
        failure, angina, and myocardial infarction within the previous six months&#xD;
&#xD;
        (x) History of malignancy, except (a) basal cell carcinoma of the skin and in situ cervical&#xD;
        carcinoma that have been excised with no recurrence or treatment within the last five&#xD;
        years, and (b) low-grade prostate cancer&#xD;
&#xD;
        (xi) Major organ allograft, or uncontrolled cardiac, hepatic, pulmonary, renal or central&#xD;
        nervous system disease, know clotting deficiency, or any illness that increases undue risk&#xD;
        to patient&#xD;
&#xD;
        (xii) History of anaphylactic reactions&#xD;
&#xD;
        (xiii) WBC count &lt;4,000/mm3; Neutrophils &lt;2,000/mm3; Platelet count &lt;125,000/mm3;&#xD;
        hemoglobin &lt;9g/dL; creatinine &gt;1.4 times the upper limit of normal; liver function test&#xD;
        &gt;1.2 times the upper limit of normal&#xD;
&#xD;
        (xiv) Presence of Hepatitis B Surface antigen (HbsAg), Hepatitis C antibody (HCVAb), and/or&#xD;
        Hepatitis C quantitative assay, or history of hepatitis (such as autoimmune hepatitis)&#xD;
        within one year prior to Screening&#xD;
&#xD;
        (xv) Presence of any confounding illness or syndromes that may interfere with proper&#xD;
        evaluation of efficacy, such as other autoimmune disease, psoriatic arthritis, lupus or&#xD;
        scleroderma&#xD;
&#xD;
        (xvi) Patients determined by the investigator (e.g., because of known or probable alcohol&#xD;
        or drug abuse) to be unreliable for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-7201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Rheumatology Research Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Medical Group Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatology Clinic of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-4976</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635-1018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.angiotec.com/clinical/clinical_studies.php</url>
    <description>Click here for more information about this study: A Phase 2, Open-Label, Clinical Study Using Intravenous Paxceed to Treat Patients with Rheumatoid Arthritis</description>
  </link>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>February 19, 2003</study_first_submitted>
  <study_first_submitted_qc>February 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2003</study_first_posted>
  <last_update_submitted>July 26, 2008</last_update_submitted>
  <last_update_submitted_qc>July 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2008</last_update_posted>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>Paxceed</keyword>
  <keyword>Micellar Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

